Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | NICE rejection of osimertinib: what does this mean for EGFR+ NSCLC in the UK?

Riyaz Shah • 29 Jan 2020
BTOG 2020
Lung Cancer Non-Small Cell Lung Cancer Erlotinib Gefitinib Osimertinib
FLAURA

The National Institute for Health and Care Excellence (NICE) in the UK has rejected osimetinib for the treatment of EGFR+ non-small cell lung cancer (NSCLC). Here, Riyaz Shah, FRCP, PhD, The Royal Marsden Hospital, London, UK, discusses this decision and what in means for the treatment of this group in the UK. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Riyaz Shah

3:17
Key insights from BTOG 2024: MARS 2 and HIT-MESO
Riyaz Shah • 18 Apr 2024
2:42
The benefits of immunotherapy versus chemotherapy: analyzing the results of the IPSOS trial
Riyaz Shah • 28 Apr 2023
2:35
CheckMate-816: what does the data tell us?
Riyaz Shah • 28 Apr 2023
2:49
SYSTEMS-2: radiotherapy in mesothelioma
Riyaz Shah • 28 Apr 2023

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals